Literature DB >> 31053597

Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer.

Shaun M O'Brien1, Astero Klampatsa2, Jeffrey C Thompson2, Marina C Martinez2, Wei-Ting Hwang3, Abishek S Rao4, Jason E Standalick4, Soyeon Kim2, Edward Cantu5, Leslie A Litzky6, Sunil Singhal4, Evgeniy B Eruslanov4, Edmund K Moon2, Steven M Albelda2.   

Abstract

Cancer progression is marked by dysfunctional tumor-infiltrating lymphocytes (TIL) with high inhibitory receptor (IR) expression. Because IR blockade has led to clinical responses in some patients with non-small cell lung cancer (NSCLC), we investigated how IRs influenced CD8+ TIL function from freshly digested early-stage NSCLC tissues using a killing assay and intracellular cytokine staining after in vitro T-cell restimulation. Early-stage lung cancer TIL function was heterogeneous with only about one third of patients showing decrements in cytokine production and lytic function. TIL hypofunction did not correlate with clinical factors, coexisting immune cells (macrophages, neutrophils, or CD4+ T regulatory cells), nor with PD-1, TIGIT, TIM-3, CD39, or CTLA-4 expression. Instead, we found that the presence of the integrin αeβ7 (CD103), characteristic of tissue-resident memory cells (TRM), was positively associated with cytokine production, whereas expression of the transcription factor Eomesodermin (Eomes) was negatively associated with TIL function. These data suggest that the functionality of CD8+ TILs from early-stage NSCLCs may be influenced by competition between an antitumor CD103+ TRM program and an exhaustion program marked by Eomes expression. Understanding the mechanisms of T-cell function in the progression of lung cancer may have clinical implications for immunotherapy. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31053597      PMCID: PMC6548666          DOI: 10.1158/2326-6066.CIR-18-0713

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  46 in total

1.  Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin.

Authors:  Andrew M Intlekofer; Naofumi Takemoto; E John Wherry; Sarah A Longworth; John T Northrup; Vikram R Palanivel; Alan C Mullen; Christopher R Gasink; Susan M Kaech; Joseph D Miller; Laurent Gapin; Kenneth Ryan; Andreas P Russ; Tullia Lindsten; Jordan S Orange; Ananda W Goldrath; Rafi Ahmed; Steven L Reiner
Journal:  Nat Immunol       Date:  2005-11-06       Impact factor: 25.606

Review 2.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

3.  CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

Authors:  Julien Fourcade; Zhaojun Sun; Ornella Pagliano; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Daniel Olive; Vijay Kuchroo; Hassane M Zarour
Journal:  Cancer Res       Date:  2011-12-28       Impact factor: 12.701

4.  Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults.

Authors:  Jaikumar Duraiswamy; Chris C Ibegbu; David Masopust; Joseph D Miller; Koichi Araki; Gregory H Doho; Pramila Tata; Satish Gupta; Michael J Zilliox; Helder I Nakaya; Bali Pulendran; W Nicholas Haining; Gordon J Freeman; Rafi Ahmed
Journal:  J Immunol       Date:  2011-03-07       Impact factor: 5.422

5.  Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory.

Authors:  Travis A Doering; Alison Crawford; Jill M Angelosanto; Michael A Paley; Carly G Ziegler; E John Wherry
Journal:  Immunity       Date:  2012-11-15       Impact factor: 31.745

6.  Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.

Authors:  Matthew J Riese; Liang-Chuan S Wang; Edmund K Moon; Rohan P Joshi; Anjana Ranganathan; Carl H June; Gary A Koretzky; Steven M Albelda
Journal:  Cancer Res       Date:  2013-04-10       Impact factor: 12.701

7.  High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention.

Authors:  Petra U Prinz; Anna N Mendler; Ilias Masouris; Leopold Durner; Ralph Oberneder; Elfriede Noessner
Journal:  J Immunol       Date:  2012-05-09       Impact factor: 5.422

8.  Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection.

Authors:  Michael A Paley; Daniela C Kroy; Pamela M Odorizzi; Jonathan B Johnnidis; Douglas V Dolfi; Burton E Barnett; Elizabeth K Bikoff; Elizabeth J Robertson; Georg M Lauer; Steven L Reiner; E John Wherry
Journal:  Science       Date:  2012-11-30       Impact factor: 47.728

9.  Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors.

Authors:  Shu-Fang Wang; Stéphane Fouquet; Maxime Chapon; Hélène Salmon; Fabienne Regnier; Karine Labroquère; Cécile Badoual; Diane Damotte; Pierre Validire; Eve Maubec; Nicolas B Delongchamps; Aurélie Cazes; Laure Gibault; Marylène Garcette; Marie-Caroline Dieu-Nosjean; Marc Zerbib; Marie-Françoise Avril; Armelle Prévost-Blondel; Clotilde Randriamampita; Alain Trautmann; Nadège Bercovici
Journal:  PLoS One       Date:  2011-03-07       Impact factor: 3.240

10.  Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.

Authors:  Lukas Baitsch; Amandine Legat; Leticia Barba; Silvia A Fuertes Marraco; Jean-Paul Rivals; Petra Baumgaertner; Céline Christiansen-Jucht; Hanifa Bouzourene; Donata Rimoldi; Hanspeter Pircher; Nathalie Rufer; Maurice Matter; Olivier Michielin; Daniel E Speiser
Journal:  PLoS One       Date:  2012-02-08       Impact factor: 3.240

View more
  37 in total

1.  Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes.

Authors:  Astero Klampatsa; Shaun M O'Brien; Jeffrey C Thompson; Abhishek S Rao; Jason E Stadanlick; Marina C Martinez; Maria Liousia; Edward Cantu; Keith Cengel; Edmund K Moon; Sunil Singhal; Evgeniy B Eruslanov; Steven M Albelda
Journal:  Oncoimmunology       Date:  2019-07-13       Impact factor: 8.110

Review 2.  Association of CD103+ T cell infiltration with overall survival in solid tumors of the digestive tract and its potential in anti-PD-1 treatment: A review and meta-analysis.

Authors:  Wei Wei; Yun Ding; Jiajia He; Jun Wu
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2022-03-28       Impact factor: 1.245

3.  Blocking TIGIT/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer.

Authors:  Lu Liu; Aihong Wang; Xiaoli Liu; Sai Han; Yu Sun; Junhua Zhang; Lingyu Guo; Youzhong Zhang
Journal:  J Transl Med       Date:  2022-06-21       Impact factor: 8.440

4.  Cellular and Molecular Profiling of Tumor Microenvironment and Early-Stage Lung Cancer.

Authors:  Radu Pirlog; Paul Chiroi; Ioana Rusu; Ancuta Maria Jurj; Liviuta Budisan; Cecilia Pop-Bica; Cornelia Braicu; Doinita Crisan; Jean-Christophe Sabourin; Ioana Berindan-Neagoe
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

5.  Shashen maidong decoction: the effect of TNF-α and IL-6 on lung cancer cachexia based on cancer toxicity theory.

Authors:  Meiyan He; Ying Luo; Lujie Chen; Manping Zeng; Qin Liao; Wencai Zhang; Hui Xie
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

Review 6.  TIGIT as an emerging immune checkpoint.

Authors:  H Harjunpää; C Guillerey
Journal:  Clin Exp Immunol       Date:  2019-12-25       Impact factor: 4.330

7.  Self-Maintaining CD103+ Cancer-Specific T Cells Are Highly Energetic with Rapid Cytotoxic and Effector Responses.

Authors:  Yanchun Peng; Tao Dong; Megat Abd Hamid; Huw Colin-York; Nasullah Khalid-Alham; Molly Browne; Lucia Cerundolo; Ji-Li Chen; Xuan Yao; Samara Rosendo-Machado; Craig Waugh; David Maldonado-Perez; Emma Bowes; Clare Verrill; Vincenzo Cerundolo; Christopher P Conlon; Marco Fritzsche
Journal:  Cancer Immunol Res       Date:  2019-11-26       Impact factor: 11.151

Review 8.  Malignant Pleural Effusions-A Window Into Local Anti-Tumor T Cell Immunity?

Authors:  Nicola Principe; Joel Kidman; Richard A Lake; Willem Joost Lesterhuis; Anna K Nowak; Alison M McDonnell; Jonathan Chee
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

Review 9.  Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.

Authors:  Jingjing Qu; Quanhui Mei; Lijun Chen; Jianying Zhou
Journal:  Cancer Immunol Immunother       Date:  2020-10-06       Impact factor: 6.968

10.  T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer.

Authors:  Richard A O'Connor; Vishwani Chauhan; Layla Mathieson; Helen Titmarsh; Lilian Koppensteiner; Irene Young; Guilia Tagliavini; David A Dorward; Sandrine Prost; Kevin Dhaliwal; William A Wallace; Ahsan R Akram
Journal:  Oncoimmunology       Date:  2021-07-08       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.